United Therapeutics Corporation Defined Benefit Plan, Amortization of Prior Service Cost (Credit)
United Therapeutics Corporation (UTHR) reported Defined Benefit Plan, Amortization of Prior Service Cost (Credit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit · last filed 2026-02-25
- United Therapeutics Corporation defined benefit plan, amortization of prior service cost (credit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- United Therapeutics Corporation defined benefit plan, amortization of prior service cost (credit) for fiscal 2024 was $200.00K, a 50.00% decline from fiscal 2023.
- United Therapeutics Corporation defined benefit plan, amortization of prior service cost (credit) for fiscal 2023 was $400.00K, a 42.86% decline from fiscal 2022.
- United Therapeutics Corporation defined benefit plan, amortization of prior service cost (credit) for fiscal 2022 was $700.00K, a 0.00% change from fiscal 2021.
| Period end | Defined Benefit Plan, Amortization of Prior Service Cost (Credit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2024-12-31 | $200.00K 10-K · filed 2026-02-25 |
| 2023-12-31 | $400.00K 10-K · filed 2026-02-25 |
| 2022-12-31 | $700.00K 10-K · filed 2025-02-26 |
| 2021-12-31 | $700.00K 10-K · filed 2024-02-21 |
| 2020-12-31 | $1.30M 10-K · filed 2023-02-22 |
| 2019-12-31 | $1.50M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |